Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc. (Nasdaq: ENSC) is a clinical-stage pharmaceutical company focused on abuse-deterrent and overdose-prevention drug technologies, operating in the specialty pharmaceutical and drug-development sector. The company entered the public markets in 2021 through a SPAC business combination and has remained listed on Nasdaq since completing that transaction. On August 6, 2026, Ensysce filed an 8-K current report with the SEC, disclosure number 0001493152-26-036268, signaling a material event requiring public notification under Exchange Act rules. The company continues to pursue its pipeline of proprietary formulations designed to deter misuse of controlled substances. For full filing details, historical SPAC transaction data, and ongoing coverage of Ensysce Biosciences, sign up for a SpacDesk account at spacdesk.com.